Cytochrome P450 2C19 polymorphism and clopidogrel after MI.
Jianting
J
Miao
Rui
R
Liu
Zhuyi
Z
Li
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D000077144:Clopidogrel; D065731:Cytochrome P-450 CYP2C19; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D011110:Polymorphism, Genetic / Q000235:genetics*; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use*; D011379:Prognosis; D012107:Research Design; D013988:Ticlopidine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D011355:Prodrugs; D000077144:Clopidogrel; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D013988:Ticlopidine